MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/medicina61091614

Медицинская библиотека · Medicina (Kaunas, Lithuania) · 2025

Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy.

Peker Pinar, Geçgel Asli, Özkan Oğuzcan, Gökmen Ivo, Menekse Serkan, Duşgun Alpay, Duman Berna Bozkurt, Çil Timuçin

СтатьяПеревод в очереди

Аннотация

Background and

Objectives

The systemic immune-inflammation index (SII), derived from peripheral blood parameters, has emerged as a novel marker reflecting the balance between host immunity and tumor-related inflammatory burden. This study aimed to investigate the prognostic impact of baseline SII on survival outcomes in patients with gastric or gastroesophageal junction (GEJ) cancer undergoing perioperative FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy. Materials and

Methods

In this retrospective study, 168 patients with histologically confirmed gastric or GEJ cancer who received perioperative FLOT therapy were included. SII was calculated using the formula: SII = (Platelets × Neutrophils)/Lymphocytes. ROC curve analysis determined the optimal SII cutoff for predicting mortality. Patients were categorized into low (SII ≤685) and high (SII >685) groups. Overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier analysis and compared via the log-rank test. Cox proportional hazards regression models were used for univariate and multivariate analysis.

Results

The optimal cutoff value for SII was determined to be 685 (AUC: 0.652, 95% CI: 0.558-0.747, p = 0.003). High SII was significantly shorter OS (17.4 vs. 28.2 months, p = 0.001) Multivariate analysis identified high SII (HR = 1.88, 95% CI: 1.36-2.89, p = 0.039), advanced T stage (HR = 3.693, p < 0.001), poor treatment response (HR = 0.36, p < 0.001), and ECOG-PS ≥1 (HR = 3.297, p < 0.001) as independent predictors of mortality.

Conclusions

Elevated baseline SII is an independent predictor of worse OS and DFS in gastric and GEJ cancer patients receiving perioperative FLOT chemotherapy. SII may serve as a practical and inexpensive biomarker to support risk stratification and personalized treatment decisions.

Для цитирования: Peker Pinar, Geçgel Asli, Özkan Oğuzcan, Gökmen Ivo, Menekse Serkan, Duşgun Alpay, Duman Berna Bozkurt, Çil Timuçin. Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy.. Medicina (Kaunas, Lithuania). 2025. DOI: 10.3390/medicina61091614.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.